As 2025 draws to a close, Nike Inc. (NYSE:NKE) finds itself at a curious crossroads. On the streets and in the gym, the "Swoosh" is regaining the cultural cachet it arguably lost during the early 2020s, fueled by a return to sport-centric innovation and high-profile collaborations. However, on Wall
Both ETFs track U.S. real estate, but their index design leads to meaningfully different portfolio behavior once market conditions and interest rates shift.
Gold has pulled back on year-end profit-taking and Dollar strength, but Fed rate cut expectations, political uncertainty, and war risks continue to support safe-haven demand. The broader uptrend remains intact.
As the final trading days of 2025 wind down, the U.S. financial sector is experiencing a period of cautious consolidation. JPMorgan Chase & Co. (NYSE: JPM), the nation’s largest lender, saw its shares ease slightly during Monday’s session, trading at $327.82—just a breath away from its
As the final trading days of 2025 wind down, the "Santa Claus Rally" that propelled financial stocks to record highs earlier this month has hit a formidable wall. Shares of major banking institutions are sliding in year-end trading as investors aggressively re-evaluate the macroeconomic outlook for 2026. The optimism that
Yesterday's Barchart article on Costco showed that COST stock is cheap. Today's article illustrates an interesting strategy: short one-month out-of-the-money COST puts and calls to pay for longer-dated in-the-money COST calls.
The historic "Hard Asset Super-Cycle" of 2025 hit a significant technical speed bump this week as gold and silver futures retreated from their highest levels in history. After a year defined by aggressive fiscal expansion and geopolitical upheaval, the precious metals market is experiencing a sharp year-end correction. As of
February WTI crude oil (CLG26 ) today is up +1.43 (+2.52%), and February RBOB gasoline (RBG26 ) is up +0.0337 (+1.97%). Crude oil prices are moving sharply higher today after weekend talks to end the Ukraine-Russian war failed to yield a breakthrough...
As the final trading days of 2025 draw to a close, the financial world is reflecting on a year defined by the "Great AI Decoupling"—a period where the market finally distinguished between companies merely talking about artificial intelligence and those deploying it at a mission-critical scale. At the epicenter
The meteoric rise of AppLovin (NASDAQ:APP) faced its most significant technical challenge of the year today as shares slipped below the psychologically critical $700 threshold. On December 29, 2025, the software giant, which has been the poster child for AI-driven advertising growth throughout the year, saw its momentum break
As the final trading week of 2025 commenced on Monday, December 29, the S&P 500 Index (SPX) experienced a measured retreat from its recently established record highs. After a year defined by the relentless expansion of artificial intelligence and a pivotal shift in monetary policy, investors appeared eager to
The gold price index is stabilizing near its all-time highs at the start of the final week of 2025. Across trading platforms, spot gold prices rose to the $4550 resistance level before settling around $4532 per ounce.
The S&P 500 Index ($SPX ) (SPY ) today is down -0.24%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.24%. March E-mini S&P futures (ESH26 ) are down -0.28%, and March E-mi...
SCHD offers diversified, tax-efficient dividend income backed by high-quality stocks, but slower growth, sector concentration, and rate sensitivity matter.
Shares of department store chain Kohl’s (NYSE:KSS)
fell 3.6% in the morning session after analyst sentiment soured amid reports of falling sales and store closures.
Shares of theater company AMC Entertainment (NYSE:AMC) fell 3.2% in the morning session after investor concerns about the company's underlying financial health overshadowed a report of strong moviegoer attendance over the final weekend of 2025. The company reported that 5.5 million people visited its theaters globally. Despite this positive attendance, the stock's decline reflected deep skepticism about the company's future. Financial data revealed significant challenges, including a substantial debt burden.
Shares of footwear company Crocs (NASDAQ:CROX)
fell 3% in the morning session after the stock tested a technical resistance level amid underlying investor concerns about slowing growth.
Shares of power resiliency solutions provider American Superconductor (NASDAQ:AMSC)
fell 3% in the morning session after the stock continued its downward slide amid a period of bearish technical sentiment.
Shares of marketing technology company Zeta Global (NYSE:ZETA) fell 3.2% in the morning session after the stock pulled back amid a broader market decline, likely as investors took profits following a strong multi-day rally.
Shares of nutrition products company Bellring Brands (NYSE:BRBR)
fell 10.5% in the morning session after analysts highlighted a murky near-term outlook and rising volatility expected for the company.
Shares of cloud software provider Upland Software (NASDAQ:UPLD) fell 2.6% in the morning session after the stock moved lower in what appeared to be a continuation of its recent downward trend, driven by technical factors.
Shares of fuel cell technology Plug Power (NASDAQ:PLUG) fell 3.3% in the morning session after the stock moved lower amid broader market weakness and continued negative momentum from previous trading sessions. The decline coincided with a weak open for the broader market, as the S&P 500 fell in the first few minutes of trading. The move extended a recent downtrend for the company. The stock had already fallen in seven of the ten previous trading days, contributing to a decline of over 12% during that period. With no major company-specific news released, the drop appeared to be influenced by the general market sentiment and the stock's existing downward trajectory.
The company’s unit secured Chinese approval for an AI-powered blood analysis device, and the stock also began trading on a reverse-split basis from Monday.
Ultragenyx Pharmaceutical announced disappointing results from its Phase 3 studies for the setrusumab (UX143) in the Osteogenesis Imperfecta (OI) program.
